Beta Bionics Inc. demonstrated strong growth in Q4 2025, with net sales increasing by 57% to $32.1 million, driven by significant expansion in the Pharmacy Benefit Plan channel. The company also saw a substantial increase in its installed customer base and new patient starts, while improving its gross margin.
Net sales for Q4 2025 reached $32.1 million, a 57% increase compared to $20.4 million in Q4 2024.
The Pharmacy Benefit Plan (PBP) channel experienced remarkable growth, with net sales up 295% to $9.8 million in Q4 2025.
The installed customer base grew by 129% to 35,011 users in Q4 2025, reflecting strong patient adoption.
Gross margin improved to 59.0% in Q4 2025, up 179 basis points from 57.2% in Q4 2024.
Beta Bionics, Inc. provided full year 2026 guidance, anticipating total revenue between $130 million and $135 million, with 36% to 38% of new patient starts reimbursed through the PBP channel, and a gross margin of 55.5% to 57.5%.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance